Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

FR0005175080
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BPCWG0
TNG

Transgene SA
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Transgene SA
ISIN
FR0005175080
TICKER
TNG
MIC
XPAR
REUTERS
TRNG.PA
BLOOMBERG
TNG FP
Tue, 03.11.2026       Transgene

Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery...
Mon, 05.10.2026       Transgene

Strasbourg, France, October 5, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting preclinical data with PoxSTG-EEV, a novel enveloped oncolytic virus designed for systemic delivery, at the Society for Immunothe...
Thu, 24.09.2026       Transgene

2026 Half-Year Results and Business Update...
Thu, 24.09.2026       Transgene

2026 Half-Year Results Report...
Thu, 24.09.2026       Transgene

Availability of Transgene’s Half-Year Financial Report as of June 30, 2026...
Tue, 08.09.2026       Transgene

Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line...
Wed, 02.09.2026       Transgene

Transgene and NEC Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications...
Tue, 07.07.2026       Transgene

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2026...
Thu, 25.06.2026       Transgene

Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate at WCID...
Mon, 22.06.2026       Transgene

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine...
Silent Ad
Tue, 26.05.2026       Transgene

TG-MVA builds on Transgene’s expertise in MVA (Modified Vaccinia Ankara) viral vectors, which are well established in smallpox vaccines development...
Fri, 22.05.2026       Transgene

Transgene’s Combined General Meeting of May 22, 2026...
Wed, 29.04.2026       Transgene

Transgene Provides Business and Financial Update for Q1 2026...
Mon, 13.04.2026       Transgene

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer...
Thu, 09.04.2026       Transgene

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 9, 2026, under number D.26-0241....
Thu, 09.04.2026       Transgene

Document d'Enregistrement Universel 2025...
Thu, 26.03.2026       Transgene

Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress...
Tue, 24.03.2026       Transgene

Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV)...
Wed, 04.02.2026       Transgene

Transgene Announces Financial Calendar for 2026...
Fri, 23.01.2026       Transgene

Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero...
Silent Ad
Mon, 12.01.2026       Transgene

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2025...
Fri, 09.01.2026       Transgene

Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse...
Wed, 17.12.2025       Transgene

Strasbourg (France), December 17, 2025, 17:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of:...
Wed, 26.11.2025       Transgene

Strasbourg, France, 27 November 2025, 00:15 a.m. CET – Transgene (Euronext Paris: TNG) had requested the suspension of trading of its shares (ISIN: FR0005175080) on Euronext Paris as from Wednesday, 26 November 2025, before market opening, pending the publication of the results of its capital increase....
Wed, 26.11.2025       Transgene

This press release may not be distributed directly or indirectly in the United States, Canada, United Kingdom, Australia or Japan....
Wed, 26.11.2025       Transgene

Instrument ID [5028] (TGNA - FR0005175080) suspended...
Tue, 25.11.2025       Transgene

Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26, 2025, before the markets open, pending the publication of the results of its capital increase....
Tue, 25.11.2025       Transgene

Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26, 2025, before the markets open, pending the publication of the results of its capital increase....
Tue, 25.11.2025       Transgene

This press release may not be distributed directly or indirectly in the United States, the United Kingdom, Canada, Australia, or Japan. ...
Tue, 25.11.2025       Transgene

This press release may not be distributed directly or indirectly in the United States, the United Kingdom, Canada, Australia, or Japan....
Thu, 06.11.2025       Transgene

Computational tool improves recombinant virus design efficiency and yield....
Mon, 20.10.2025       Transgene

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions...
Mon, 13.10.2025       Transgene

Poster presentation on BT-001 in combination with pembrolizumab has shown tumor shrinkage in both injected and non-injected lesions...
Fri, 03.10.2025       Transgene

Strasbourg, France, October 3, 2025, 5:45 p.m.  CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeuti...
Tue, 16.09.2025       Transgene

2025 Half-Year Results and Business Update...
Tue, 16.09.2025       Transgene

2025 Half-year financial information...
Tue, 16.09.2025       Transgene

TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2025....
Mon, 28.07.2025       Transgene

Poster presentation of updated data on BT-001 from the Phase I part of the ongoing Phase I/IIa study in solid tumors...
Wed, 09.07.2025       Transgene

Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors. She succeeds Philippe Archinard, who is retiring from the B...
Tue, 08.07.2025       Transgene

Strasbourg, July 8, 2025 – 06:00 pm CET...
Thu, 19.06.2025       Transgene

Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050...
Fri, 13.06.2025       Transgene

Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of:...
Tue, 03.06.2025       Transgene

Strasbourg (France), June 3, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced it will host a live webcast to discuss the latest positive clinical data from its individualized neoantigen cancer vaccine, TG4050, presented at the...
Sun, 01.06.2025       Transgene

All patients in the treatment arm remain disease-free after a minimum of 2-year follow-up in the randomized Phase I trial in resected HPV-negative locally advanced head and neck cancer – Demonstrating clinical proof of principle for TG4050...
Thu, 22.05.2025       Transgene

24-month follow-up data from randomized Phase I part of the Phase I/II trial of TG4050 in resected locally advanced head and neck cancer selected for rapid oral presentationat ASCO on June 1st, 2025...
Thu, 24.04.2025       Transgene

TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025...
Thu, 24.04.2025       Transgene

Strasbourg, France, April 24, 2025, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available....
Thu, 10.04.2025       Transgene

Document d'Enregistrement Universel 2024...
Thu, 10.04.2025       Transgene

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 10, 2025, under number D.25-0243....
Thu, 27.03.2025       Transgene

2024 Full-year results and business update...